Immunocore Holdings - ADR opened at $31.65, in line with its previous close of $31.65. In the last trading session, the stock traded between $30.51 and $31.65. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Immunocore Holdings - ADR is now worth
$ 77.52
Resulting in a loss of
$ 22.48 (22.48%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
60%
Hold
40%
Sell
0%
Markets Today
Today's Change
$-1.16 (-3.67%)
Day High
$31.65
Day Low
$30.51
Day Open
$31.65
Prev Close
$31.65
Volume
4,20,424
1W Return
4.34%
1M Return
4.80%
3M Return
-10.81%
6M Return
5.68%
1Y Return
-13.38%
Fundamentals
Market Cap ($ Mn)
1,576
PE Ratio
-
PB Ratio
4.49
PEG Ratio
-
ROE
-9.32%
ROCE
-2.70%
EPS (TTM)
$-0.28
Investment Returns
1 Week
4.34%
1 Month
4.80%
3 Months
-10.81%
6 Months
5.68%
9 Months
-7.41%
Financials
Quarterly
All values in $ Mn
93.9
Mar 25
98.0
Jun 25
103.7
Sep 25
104.5
Dec 25
115.9
Jun 26
102.2
Sep 26
Updates
10Nov
HC Wainwright maintains Buy on Immunocore, cuts price target to $80
HC Wainwright maintains Buy rating on Immunocore Holdings. Price target lowered from $100 to $80. Analyst Patrick R. Trucchio issued the update.
2 days ago
6Nov
Immunocore reports 70% 2-year survival in uveal melanoma combo trial
Two-year overall survival rate reached 70% for first-line patients receiving brenetafusp plus KIMMTRAK. Combination therapy achieved a 29% overall response rate with a median duration of response of 24.1 months. Median progression-free survival improved to 8.1 months for the combination versus 4.2 months for monotherapy. Immunocore plans to launch a randomized Phase 2/3 trial, DUET-UVEAL, based on these positive Phase 1/2 results.
6 days ago
6Nov
Immunocore Holdings Q3 Results: Loss widens to $(0.28), sales miss estimates
Immunocore Holdings posted a Q3 loss of $(0.28) per share, missing the $(0.10) estimate by 180%. Quarterly sales stood at $102.222 million, falling short of the $113.438 million consensus. Revenue declined 1.42% year-over-year from $103.693 million in the prior year period.
6 days ago
15Oct
Immunocore doses first patient in Phase 1 trial for type 1 diabetes
First patient dosed in Phase 1 trial of IMC-S118AI for type 1 diabetes. IMC-S118AI is Immunocore's first autoimmune disease candidate. Trial targets HLA-A*02:01-positive patients to preserve beta cell mass. Preclinical data published in Science Advances supports tissue-specific mechanism.
28 days ago
14Sep
Immunocore hits target enrollment in Phase 3 melanoma trial
Immunocore achieved target enrollment of 540 patients in Phase 3 TEBE-AM trial. Trial evaluates KIMMTRAK monotherapy and combination with pembrolizumab. Primary endpoint is overall survival in HLA-A*02:01-positive advanced melanoma. Topline data expected as early as end of 2026. Company cites unmet need for up to 4,000 patients in US and Europe.
